American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 816-824.e1 , May 2009

Central Retinal Sensitivity After Intravitreal Injection of Bevacizumab for Myopic Choroidal Neovascularization

,Accepted 24 November 2008.

References 

  1. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol. 2008;53:121–138
  2. Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89:1522–1528
  3. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110:1297–1305
  4. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP Report No. 3. Ophthalmology. 2003;110:667–673
  5. Bevacizumab (Anti-VEGF monoclonal antibody, Avastin, rhumab-VEGF). Drugs R D. 2002;3:28–30
  6. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383–390
  7. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354–356
  8. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695–1705
  9. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190–2196
  10. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina. 2007;27:707–712
  11. Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina. 2006;26:960–963
  12. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol. 2007;17:620–626
  13. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. Forthcoming.
  14. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol. 2007;91:161–165
  15. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina. 2006;26:1093–1094
  16. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157–160
  17. Varano M, Parisi V, Tedeschi M, et al. Macular function after PDT in myopic maculopathy: psychophysical and electrophysiological evaluation. Invest Ophthalmol Vis Sci. 2005;46:1453–1462
  18. Rohrschneider K, Springer C, Bültmann S, Völcker HE. Microperimetry–comparison between the Micro Perimeter-1 and scanning laser ophthalmoscope–fundus perimetry. Am J Ophthalmol. 2005;139:125–134
  19. Springer C, Bültmann S, Völcker HE, Rohrschneider K. Fundus perimetry with the Micro Perimeter-1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology. 2005;112:848–854
  20. Yodoi Y, Tsujikawa A, Kameda T, et al. Central retinal sensitivity measured with the Micro Perimeter-1 after photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;143:984–994
  21. Weingessel B, Sacu S, Vécsei-Marlovits PV, et al. Interexaminer and intraexaminer reliability of the microperimeter MP-1. Eye. Forthcoming.
  22. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456–462
  23. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol. 2005;89:1368–1370
  24. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol. 2008;145:518–526
  25. Kojima A, Ohno-Matsui K, Futagami S, et al. Trans-Tenon's retrobulbar triamcinol1 infusion for myopic choroidal neovascularization. Acta Ophthalmol Scand. 2006;84:749–754
  26. Spandau UH, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2006;142:1068–1070

PII: S0002-9394(08)00901-X

doi: 10.1016/j.ajo.2008.11.020

American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 816-824.e1 , May 2009

Article Tools

* Image Usage & Resolution